

ASSIGNMENT

Whereas, **SCHRÖDINGER, LLC**, having its principal place of business at 1540 Broadway, 24th Floor, New York, NY 10036-4041, for valuable consideration received from **MORPHIC THERAPEUTIC, INC.**, having its principal place of business at 35 Gatehouse Drive A2, Waltham, MA 02451, the receipt of which is hereby acknowledged, do hereby sell, assign and transfer unto said

MORPHIC THERAPEUTIC, INC.

its successors and assigns, the entire interest for the United States of America and all foreign countries including all rights of priority under the International Convention for the Protection of Industrial Property in a certain invention or improvement in

“INHIBITING HUMAN INTEGRIN ALPHA-4 BETA-7”

described in United States Provisional Patent Application Serial Nos. 63/583,193, filed on September 15, 2023, and 63/687,191, filed on August 26, 2024, in the United States Patent and Trademark Office, and in all Letters Patent of the United States and all foreign countries which may or shall be granted on said invention, or any parts thereof, or on said application, or any divisional, continuing, reissue or other applications based in whole or in part thereon. And we agree, for ourselves and our executors and administrators, with said corporation and its successors and assigns but at its or their expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to said corporation, with specifications and claims in such form as shall be approved by the counsel of said corporation and to vest and confirm in said corporation, its successors and assigns, the legal title to all such patents.

And we do hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said corporation, its successors and assigns.

MORF-017USP1/USP2

SCHRÖDINGER, LLC

Date: September 10, 2024

By: 
19630E280E31405
Printed Name: Ramy Farid
Title: President & CEO

WITNESSED BY:


E23A8DEA3EC2493
Printed Name: Laura Madden
Date: September 10, 2024

WITNESSED BY:


12121CABE1F848F
Printed Name: William Littman
Date: September 10, 2024

ACCEPTANCE:

Morphic Therapeutic, Inc., hereby declares that it accepts the rights and property hereby assigned and transferred to it.

MORPHIC THERAPEUTIC, INC.

By: 
Elizabeth A. McGraw
Printed Name: _____
Title: Vice President, Assistant General Patent Counsel, Eli Lilly and Company of which Morphic Therapeutic, Inc., is a wholly owned subsidiary